Venus Concept Announces the Launch of its latest generation of ARTAS iX, the World’s Most Advanced Robotic Hair Restoration System
March 20 2023 - 7:00AM
Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:
VERO), a global medical aesthetic technology leader, announced
today the launch of its latest generation of ARTAS iX, which is now
broadly available to physicians specializing in hair
transplantation worldwide.
Its latest generation of ARTAS iX sets a new
standard for hair transplantation by leveraging cutting-edge
robotics, machine vision, artificial intelligence, and machine
learning technologies. This advanced system offers a new level of
speed to the implantation process, now allowing the implantation of
up to 1000 grafts per hour while also improving the speed of
harvesting, resulting in a procedure that is up to 25% faster.
Additional improvements include the new vision system, which
improves patient tracking and follicle centering, resulting in
better graft quality and enhanced precision. In addition to these
significant hardware advancements, our enhanced software enables an
improved, intuitive user experience with a refreshed user interface
and a new training mode to enable smoother training of
practitioners and run real-time demos during consultations.
"We continue to focus on integrating the
advancements of robotics and artificial intelligence into the area
of minimally-invasive aesthetic and hair restoration procedures,”
said Dr. Hemanth Varghese, President and Chief Innovation &
Business Officer of Venus Concept. "The market for hair restoration
continues to grow, and with it, the demand for better solutions to
optimize procedure workflow and clinical outcomes. Our enhanced
ARTAS iX system marks another major achievement for our Robotics
Center of Excellence in its continuous innovation towards
revolutionizing hair transplantation. The system enables physicians
to generate unparalleled results offering state-of-the-art
precision and accuracy levels as well as speed, helping to address
concerns related to the labor-intensive aspects of hair restoration
procedures such as clinical fatigue and procedure time. Hair
restoration is an important segment for Venus Concept and will
continue to be a driver of growth into the future. "
"I have found that the new upgrades to the ARTAS
iX system significantly improve the process of transplantation,
handling of harvested grafts, site-making and implantation, all of
which contribute to reducing training time and increasing staff
bandwidth," commented Dr. Maxim Chumak, an ARTAS iX system user and
a diplomate of the American Board of Hair Restoration Surgery.
"Most of the devices currently on the market require manual
operation for harvesting and for implanters to be loaded
individually, which can be time-consuming and can potentially
damage grafts. This is the first system that requires minimal
handling of the grafts, effectively addressing this issue. "
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 15
direct markets. Venus Concept’s product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve, Venus Viva MD and AI.ME. Venus
Concept’s hair restoration systems include NeoGraft® and the ARTAS
iX® Robotic Hair Restoration system. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Nov 2023 to Nov 2024